Interestingly, either a genetic reduction of ADAM17 expression or pharmacological inhibition of ADAM17 in HFD-fed mice partially protected from obesity and insulin resistance compared with wild-type mice [10,11], suggesting that ADAM17 is an important mediator in the development of obesity-induced metabolic disorders. This evidence concerns the gene ADAM17 and Other metabolic disease.